The Neurotechnology Industry 2006 Report is finally finished and available.
Neurotechnology Revenues Reach $110 Billion Says New Report on the Brain Industry: NeuroInsights Reveals Investment Trends, Market Opportunities and Product Pipelines of 450 Neurotech Companies
SAN FRANCISCO--(BUSINESS WIRE)--April 18, 2006--NeuroInsights, the neurotechnology market authority, today announced the release of the industry's second annual comprehensive investment and business analysis of the global neurotechnology marketplace. In the report, NeuroInsights provides a unified market-based framework to help investors, companies, and governments easily quantify opportunities, determine risks and understand the dynamics of this rapidly changing market.
"The Neurotechnology Industry 2006 Report: Market Analysis and Strategic Investment Guide of the Global Neurological Disease and Psychiatric Illness Markets," is a 330-page report tracking developments at over 450 public and private companies involved in neurotech. The report includes competitive analysis and clinical trials by market segment for more than a dozen disorders, including Alzheimer's disease, addiction, anxiety, attention disorders, depression, epilepsy, hearing loss, insomnia, obesity, pain, Parkinson's, schizophrenia, stroke and other brain-related illnesses.
The Neurotechnology Industry 2006 Report's findings include:
-- Neurotech products generated revenues of $110 billion in 2005 with 10% growth. The three sectors contributed as follows: neuropharmaceuticals with revenues of $93 billion and 7% growth; neurodevices with revenues of $3.4 billion and 21% growth; and neurodiagnostics with revenues of $13.5 billion and 11% growth.
-- Venture capital investment in neurotech companies climbed 230% from 1999 to 2005, representing nearly $7.5 billion. Today, one-in-four VC dollars invested in life sciences goes to neurotechnology companies.
-- NeuroInsights' Neurotech Index, an investment benchmark that measures the stock performance of 30 publicly traded neurotechnology companies, which was started December 31, 2003, was up 85%, as of March 31st, 2006, compared to gains of 16% in both the S&P 500 and the NASDAQ Composite Index.
-- Neurological disease and psychiatric illness represent the largest and fastest growing unmet medical market: over 1.5 billion people worldwide and 100 million individuals in North America alone.
"2005 was another solid growth year for neurotech companies with heavy merger and acquisition activity," said Zack Lynch, managing director of NeuroInsights. "In 2005, new drugs and devices were approved for unmet medical needs in insomnia, depression, and stroke. Substantial venture investment, particularly in specialty pharmaceuticals and neurodevices, continues to drive future growth."
Developments in the neurotechnology industry will be discussed at NeuroInsights' annual Neurotech Industry Investing and Business Conference to be held on May 18th, 2006, at the Westin San Francisco in Millbrae, California. The market-defining conference will feature 40 neurotech executives and investors discussing the critical trends driving the development new drugs, devices and diagnostics for the brain and nervous system.
Pricing and Availability
"The Neurotechnology Industry 2006 Report: Market Analysis and Strategic Investment Guide of the Global Neurological Disease and Psychiatric Illness Markets" is available immediately. The cost of the report is $4,500 and can be ordered directly at www.neuroinsights.com or by calling 415-229-3225.